Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype.

Sánchez-Cenizo L, Formentini L, Aldea M, Ortega AD, García-Huerta P, Sánchez-Aragó M, Cuezva JM.

J Biol Chem. 2010 Aug 13;285(33):25308-13. doi: 10.1074/jbc.M110.146480. Epub 2010 Jun 9.

2.

The ATPase Inhibitory Factor 1 (IF1): A master regulator of energy metabolism and of cell survival.

García-Bermúdez J, Cuezva JM.

Biochim Biophys Acta. 2016 Aug;1857(8):1167-82. doi: 10.1016/j.bbabio.2016.02.004. Epub 2016 Feb 12.

PMID:
26876430
3.

PKA Phosphorylates the ATPase Inhibitory Factor 1 and Inactivates Its Capacity to Bind and Inhibit the Mitochondrial H(+)-ATP Synthase.

García-Bermúdez J, Sánchez-Aragó M, Soldevilla B, Del Arco A, Nuevo-Tapioles C, Cuezva JM.

Cell Rep. 2015 Sep 29;12(12):2143-55. doi: 10.1016/j.celrep.2015.08.052. Epub 2015 Sep 17.

4.

Glucose-modulated mitochondria adaptation in tumor cells: a focus on ATP synthase and inhibitor Factor 1.

Domenis R, Bisetto E, Rossi D, Comelli M, Mavelli I.

Int J Mol Sci. 2012;13(2):1933-50. doi: 10.3390/ijms13021933. Epub 2012 Feb 10.

5.

In vivo inhibition of the mitochondrial H+-ATP synthase in neurons promotes metabolic preconditioning.

Formentini L, Pereira MP, Sánchez-Cenizo L, Santacatterina F, Lucas JJ, Navarro C, Martínez-Serrano A, Cuezva JM.

EMBO J. 2014 Apr 1;33(7):762-78. doi: 10.1002/embj.201386392. Epub 2014 Feb 12.

6.

The inhibitor protein (IF1) of the F1F0-ATPase modulates human osteosarcoma cell bioenergetics.

Barbato S, Sgarbi G, Gorini G, Baracca A, Solaini G.

J Biol Chem. 2015 Mar 6;290(10):6338-48. doi: 10.1074/jbc.M114.631788. Epub 2015 Jan 20.

7.

Overexpression of the ATPase Inhibitory Factor 1 Favors a Non-metastatic Phenotype in Breast Cancer.

García-Ledo L, Nuevo-Tapioles C, Cuevas-Martín C, Martínez-Reyes I, Soldevilla B, González-Llorente L, Cuezva JM.

Front Oncol. 2017 Apr 10;7:69. doi: 10.3389/fonc.2017.00069. eCollection 2017.

8.

Post-transcriptional regulation of the mitochondrial H(+)-ATP synthase: a key regulator of the metabolic phenotype in cancer.

Willers IM, Cuezva JM.

Biochim Biophys Acta. 2011 Jun;1807(6):543-51. doi: 10.1016/j.bbabio.2010.10.016. Epub 2010 Oct 27. Review.

9.

Mitochondrial bioenergetic profile and responses to metabolic inhibition in human hepatocarcinoma cell lines with distinct differentiation characteristics.

Domenis R, Comelli M, Bisetto E, Mavelli I.

J Bioenerg Biomembr. 2011 Oct;43(5):493-505. doi: 10.1007/s10863-011-9380-5. Epub 2011 Sep 1.

PMID:
21882038
10.

[Research on relevance between mitochondrial ATP synthase and malignant tumor].

Wang J, Li R, Zhang G.

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2014 Jun;31(3):714-7. Review. Chinese.

PMID:
25219263
11.

IF1, a natural inhibitor of mitochondrial ATP synthase, is not essential for the normal growth and breeding of mice.

Nakamura J, Fujikawa M, Yoshida M.

Biosci Rep. 2013 Sep 17;33(5). pii: e00067. doi: 10.1042/BSR20130078.

12.

The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells.

Vazquez-Martin A, Corominas-Faja B, Cufi S, Vellon L, Oliveras-Ferraros C, Menendez OJ, Joven J, Lupu R, Menendez JA.

Cell Cycle. 2013 Jan 15;12(2):207-18. doi: 10.4161/cc.23352. Epub 2012 Jan 15. Review.

13.

Investigation of the role and mechanism of IF1 and STF1 proteins, twin inhibitory peptides which interact with the yeast mitochondrial ATP synthase.

Venard R, Brèthes D, Giraud MF, Vaillier J, Velours J, Haraux F.

Biochemistry. 2003 Jun 24;42(24):7626-36.

PMID:
12809520
14.

Supercomplexes and subcomplexes of mitochondrial oxidative phosphorylation.

Wittig I, Carrozzo R, Santorelli FM, Schägger H.

Biochim Biophys Acta. 2006 Sep-Oct;1757(9-10):1066-72. Epub 2006 May 12.

15.

Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance.

Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung MS, Lim SJ, Park JG.

Cancer Res. 2005 Apr 15;65(8):3162-70.

16.

The H(+)-ATP synthase: a gate to ROS-mediated cell death or cell survival.

Martínez-Reyes I, Cuezva JM.

Biochim Biophys Acta. 2014 Jul;1837(7):1099-112. doi: 10.1016/j.bbabio.2014.03.010. Epub 2014 Mar 28. Review.

17.

Consequences of the pathogenic T9176C mutation of human mitochondrial DNA on yeast mitochondrial ATP synthase.

Kucharczyk R, Ezkurdia N, Couplan E, Procaccio V, Ackerman SH, Blondel M, di Rago JP.

Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1105-12. doi: 10.1016/j.bbabio.2009.12.022. Epub 2010 Jan 4.

18.

Expression, regulation and clinical relevance of the ATPase inhibitory factor 1 in human cancers.

Sánchez-Aragó M, Formentini L, Martínez-Reyes I, García-Bermudez J, Santacatterina F, Sánchez-Cenizo L, Willers IM, Aldea M, Nájera L, Juarránz A, López EC, Clofent J, Navarro C, Espinosa E, Cuezva JM.

Oncogenesis. 2013 Apr 22;2:e46. doi: 10.1038/oncsis.2013.9.

19.

Suppression of mitochondrial ATPase inhibitor protein (IF1) in the liver of late septic rats.

Huang LJ, Hsu C, Tsai TN, Wang SJ, Yang RC.

Biochim Biophys Acta. 2007 Jul;1767(7):888-96. Epub 2007 Apr 3.

20.

The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response.

Formentini L, Sánchez-Aragó M, Sánchez-Cenizo L, Cuezva JM.

Mol Cell. 2012 Mar 30;45(6):731-42. doi: 10.1016/j.molcel.2012.01.008. Epub 2012 Feb 16.

Supplemental Content

Support Center